Cerus Endovascular today announced the appointment of Stephen Griffin to chief executive officer, effective immediately.
Griffin has been with the company since 2014 and has served as president since 2018. He played a critical role in assembling the current Fremont, California-based company’s team and helped establish the Contour brand internationally.
“Stephen played a vital role in helping me create and execute our strategic plan as well as navigating the various regulatory and commercial hurdles in order to achieve our current level of commercial and technical success,” Chairperson Sam Milstein said in a news release. “Not only has Stephen been the key inventor behind all of the company’s implant product portfolio but the high regard with which he is held by his peers has been invaluable in affirming the credibility of the company’s technical and commercial platform.”
Prior to joining the company, Griffin was a medical device design and technology consultant. He also served as the VP of research & development for Covidien, now a part of Medtronic and has held varying roles in R&D at Nellix Endovascular, Johnson & Johnson and Boston Scientific.
“I am truly honored to accept this role and will continue to give my 100% effort in expanding our global footprint with our portfolio of products,” Griffin said. “I continue to be excited about the potential of our products and the impact that they already have and will have on patients and their families. I am blessed to have a job I love and to work with so many incredibly smart people. My work never gets old.”
